BTG - Brochure 2018

ess, y.

Driving quality across the biologic supply chain

gether

er’s bottom line our top ocess—from discovery through a complete line of integrated culture to purification, analytics, complex world of producing ose a partner with the vision to

ssing solutions at P R O J E C T S P ON S OR n

Transforming the biologic supply chain through digitisation

TOTAL GLOBAL BIOLOGICS SPENDING HAS GROWN FROM $46BN IN 2002 TO A STAGGERING $221BN IN 2017. BTG’S HEAD OF SUPPLY CHAIN, ALON BEN DROR, DISCUSSES HOW ITS DIGITISED SUPPLY CHAIN WILL ENSURE THE COMPANY REMAINS A KEY PLAYER WORLDWIDE WRIT TEN BY

CATHERINE STURMAN

PRODUCED BY

HEYKEL OUNI

e u r o p e . b u s iw n ewsw. s cbht g i ei f. l.com

0

ne of the first biologic companies in Israel, Bio Technology General (BTG) has become one of the most

highly respected businesses in the industry.

Housing significant expertise, the company supports startups in the country and is responsible for the development, production and marketing of growth hormone Somatropin, EUFLEXXA for osteoarthritis sufferers and Biolon for ophthalmic surgeries. The company also responsible for the production of new API for fertility treatment - Recovelle Driving high quality standards across its operations, BTG has been recognised by the Israeli Ministry of Health for its commitment and unwavering focus on delivering high quality pharmaceuticals, which are commercialised in over 40 countries. The company is also set to see an investment of up to $15mn by its parent company, Ferring Pharmaceuticals, to expand its production capabilities in a mammalian cells operation for the production of fertility medicine.

“We are having a lot of audits from different regulatory authorities each year and are passing all of them with ease. We are very proud of our quality, systems and processes,” explains Head of Supply Chain, Alon Ben Dror.

Responsible for planning control, logistics, business technology, as well as BTG’s pro-

“ We need to ensure medicine supplied in high quality, which means controlled shipment and logistics routes, making sure we have the right safety stock for each market”

­­ —

Alon Ben Dror, Head of Supply Chain

curement activities, encompassing

ble for getting demand from the

direct and indirect costs, Alon has

markets through the ERP system, in

spearheaded the transformation

order to create work plans for produc-

of BTG’s supply chain processes,

tion and quality control. The logistics

placing the patient (or customer)

group manages our warehouses, raw

firmly at the helm.

material, packaging material and our

“Sometimes the customer is the

general technical warehouse. Thirdly,

patient but it can be a hospital or clinic.

the business technology element

We need to ensure medicine is sup-

encompasses two different areas, our

plied in high quality, which means

control system and automation, the

controlled shipment and logistics

other being IT.”

routes, making sure we have the right safety stock for each market,” he says.

IMPLEMENTING LEAN PROCESSES

“Planning and control are responsi-

By combining its IT and supply chain e u r o p e . b u s iw n ewsw. s cbht g i ei f. l.com

operations, BTG has digitised its processes to become not only lean, but responsive to any issues or surges in demand across the supply chain.

Implementing a central automation system

by Emerson, the company has gained the ability to control many of its production processes and visually look at all data received to better understand various trends.

“We’ve connected our quality control system to our production system so processes are interfaced with each other and enable a quicker transformation of information and therefore better coordination and release time,” reflects Alon.

“This has allowed us to further plan our logistics: how soon we can ship products, keep less inventory and reduce our cycle time. This is a big advantage for us. Our ERP system is also connected to the global organisation, so the market and global supply chain can see where things are in each point of time.”

DEVELOPING NEW PRODUCTS

Such is the company’s growth, its $15mn investment from Ferring will help BTG to expand its production capabilities, utilise new technologies and develop new production lines to promote the growth of its products and services. An area of increased

focus is the manufacturing of fertility treatment Rekovelle, which will cater to ongoing global demands.

“This product is going to be manufactured at several sites at Ferring, and we will also have a backup site in Switzerland. This FACT

• One of the first biotechnology companies in Israel • BTG supports the growing number of startups in the country • BTG develops, produces and markets growth hormone Somatropin, EUFLEXXA for osteoarthritis sufferers, Biolin for ophthalmic surgeries and Recovelle for fertility treatment • Recognised by the Israeli Ministry of Health for its commitment and unwavering focus on delivering high quality pharmaceuticals • The company has received a $15mn from its parent company, Ferring Pharmaceuticals to expand its production capabilities

investment will enable us to enhance the biotech process in bio reactors and the product is derived from mammalian cells,” says Ben Dror.

However, communication across the organisation will remain a global challenge across the business. Supplying over 40 countries, BTG has worked to build trust and transparency, and regularly meets with all involved parties to guarantee mutually beneficial relationships.

“It is important to be clear with our messages and to be very transparent with the information given to highlight that we are in this together,” Ben Dror adds.

“Another challenge is that in many cases we have only one supplier. It is therefore important for us to maintain this relationship with suppliers and make them partners. This creates an environment where the supplier will also experience success. The supplier is crucial to the success of our organisation.”

METHODOLOGY OF SAFETY

Additionally, in such a high cost, and highly e u r o p e . b u s iw n ewsw. s cbht g i ei f. l.com

Your process, our priority.

Let’s move forward together We’ve built our business on making the customer’s bottom line our top concern. With applications that span your bioprocess—from discovery through large-scale commercial production—we provide a complete line of integrated solutions from single-use technologies and cell culture to purification, analytics, and logistical services. So when it comes to the complex world of producing biologics-based therapeutics and vaccines, choose a partner with the vision to make yours a reality.

Experience our integrated bioprocessing solutions at thermofisher.com/bioproduction For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals. © 2018 Thermo Fisher Scientifi c Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientifi c and its subsidiaries unless otherwise specifi ed. COL16666 0518

regulated environment, it is imperative for the business to mitigate

Ben Dror.

“We also have an SQDEC meth-

ongoing risks. Processes at BTG

odology, which stands for safety,

have been designed on a methodol-

quality, delivery, employee and cost.

ogy of safety, starting at ground

This is the base of the KPI structure

level.

at the organisation. We start with

“The first thing is to design your

safety as its most important thing,

processes the right way. The sec-

then move to quality. After that, it’s

ond thing is implementing a high

my responsibility to deliver and

awareness of safety culture. We

make sure patients and customers

have a safety programme, named

receive goods on time in full. Last

‘Safety Through Leadership’, where

but definitely not least, we have the

we train our team leaders, all the

employees. It is crucial for the

managers in the organisation and

organisation to make sure we have

also some employees to put safety

the right people in the right posi-

as part of their leadership,” notes

tions with a proper development w w w. b t g i l . c o m

TOTAL LOGISTICS SOLUTIONS HIGHLY REGULATED, CERTIFIED AND PROFESSIONAL SUPPLY CHAIN • • •

Fully controlled – GDP Compatible Flexible capacities & capabilities.

Audited successfully by pharma companies & Merck

AUTHORIZED TO SELL, STORE & DISTRIBUTE BY AUTHORITIES (MOH, MOE, MOT): • • • •

Pharma & Cosmetics raw material Food raw materials IVD Products Authorized Dangerous goods storage & distribution

Mercury@mercury-ltd.co.il

www.mercury-ltd.co.il

Authorized distributor of

Integrated Upstream Platform - From Cell Line to Manufacturing Sartorius Stedim Biotech has come up with the first fully integrated upstream platform: It connects a top-performing expression system with outstanding equipment and process control for the rapid development and scale-up of robust, high-titer commercial manufacturing processes. www.connect-upstream.com Speed to Clinic

Increased Titers

Quality by Design

Robust Production

“ We’ve connected our quality control system to our production system so processes are interfaced with each other and enable a quicker transformation of information and therefore better coordination and release time” ­­ —

Alon Ben Dror, Head of Supply Chain

plan. If we are able to succeed with the

operations, BTG will continue to house

four elements then the fifth, which is

significant expertise and remain a key

cost, will go down naturally.”

player in the biotechnology market.

Factoring in safety as part of its lean

“I see new ideas every day while we

culture, BTG has significantly reduced

are moving forward. BTG management

the number of risks across its opera-

is also focusing on new opportunities,”

tions and undertakes a number of

he concludes. “And with a strong

activities to protect the environment,

backup that we got from Ferring man-

such as filtering out harmful chemicals

agement, I believe that the future for

and neutralising materials before they

BTG is to keep growing and to be a

are thrown into drainage systems.

leading entity within the Ferring global

Delivering what Ben Dror describes

organisation.”

as “the full package” across its

e u r o p e . b u s iw n ewsw. s cbht g i ei f. l.com

Bio-Technology General (Israel) Ltd., Be’er Tuvia Industrial Zone, P.O. Box 571, Kiryat Malachi, 8310402 Israel. www.btgil.com